Day One - GMT (Greenwich Mean Time, GMTZ)
- Adam Griffiths - Portfolio Manager, LSX
- Alexander Zehnder - CEO, CureVac
- Laura Lane - Vice President Venture Science (Head of Europe), Eli Lilly & Co. Ltd.
- Matthew Edwards - Partner, Brown Rudnick
- Anta Gkelou - Partner, Sofinnova Partners
- Regina Hodits - Managing Director, Angelini Ventures
- Tim Haines - Executive Partner, Abingworth
- Jack Giles - Conference Producer, LSX
- Diana Saraceni - General Partner, Panakès Partners
- Robert Kossmann - Global Head of Medical Affairs, Fresenius Medical Care
- Carolina Aguilar - CEO & Co-Founder, INBRAIN Neuroelectronics
- Carla Goulart Peron - Chief Medical Officer, Philips
- Ibraheem Elmogy - General Manager, Science & Technology, International, GE HealthCare
- Barnaby Pickering - Public Relations Associate, RHA Communications
- Tejas Atawane - Corporate Development Leader, Enterprise Informatics, Philips
- Juergen Simon - VP, Technology Strategy & Head of Siemens Healthineers Technology Accelerator, Siemens Healthineers
- Anthony Vallance-Owen - Senior Investment Manager, Werfen
- Nir Goldenberg - Director, Technology Development, Mayo Clinic Ventures
- Ryan McGuinness - GM Corporate Growth Lab, Triple Ring Technologies
- Nadia Konneh - Senior Conference Director, Healthtech Lead, LSX
- Betsabeh Madani-Hermann - Global Head of Research, Philips
- Mark Davies - Chief Health Officer, IBM
- Beth Wolff - Director Digital Health Solutions, Global Corporate Strategy & BD, Lundbeck
- Emre Ozcan - SVP, Global Head of Digital Health & Devices, Merck
- Matthew Arentz - Director of Precision Health, Novartis Foundation
- Marko Kuisma - Partner, Innovestor
- Esther Reynal de St Michel Richardot - Founding General Partner, THENA Capital
- Anna Klepchukova - Chief Medical Officer, Flo Health
- Eleonora Benhar - VP of Science & Data, Natural Cycles
- Ekaterina Gianelli - Venture Partner, Calm/Storm
- Diana Torgersen - Head of Innovation Ecosystem Integration, Organon
- Caoimhe Vallely-Gilroy - Director Healthtech Strategy and Pharma - DayOne, Basel Area Business & Innovation
M&A Masterclass
Part 1:
- How can M&A impact your business?
- What alternatives are there?
- M&A lifecycle:
- Preparing for M&A
- Consideration mechanics
- Doing the deal
- Integration
- Anti-trust/FDI – More transactions caught as scope of regulatory review broadens
Part 2: Fireside chat: How to Turn a 10-Person Biotech into a $1.1Bn Acquisition in 7 Years
Renee Aguiar-Lucander, Former CEO, Calliditas
- Motivation Behind the Acquisition
- Process Overview
- Outcome and Lessons Learned
- Future Considerations
Part 3:
- Open Floor for Questions
- How to prepare a biotech company for M&A discussions?
- What specific attributes do buyers look for in a biotech firm?
- How can biotechs leverage M&A as a growth strategy?
- Wrap-Up Discussion
- Summarize key takeaways from the workshop.
- Highlight actionable insights for biotech companies considering M&A
- Renee Aguiar-Lucander - Chief Executive Officer, Calliditas Therapeutics
- Victoria Rhodes - Partner - Corporate, M&A, Capital Markets, DLA Piper
- Joost Haans - Partner, DLA Piper
- Maha Radhakrishnan - Executive Partner, Sofinnova Investments
- Amanda Gett - Partner, Kurma Partners
- Michael White - Head of Life Sciences, HSBC Innovation Bank, EMEA
- Luc Dochez - Managing Partner, DROIA Ventures
- João Incio - General Partner, Biovance Capital
- Daniela Begolo - Managing Director, EQT Life Sciences
- Arvind Shandilya - Associate, Calculus Capital
- Kelly Provost - Partner, Head of Life Sciences Capital Markets, CFGI
- Thomas Thestrup - Senior Principal, Angelini Ventures
- Mukul Mohanty - Senior Partner, Truffle Capital
- Giovanni Rizzo - Partner Biotech Fund, Indaco Venture Partners
- David Jenkins - SVP, Research and External Innovation, Ipsen
- Gwilym Attwell - Principal, Fish & Richardson P.C.
- Chris Brown - Executive Director, Business Development Transaction, GSK
- Duncan Young - Executive Director, Oncology R&D Business Development, AstraZeneca
- Carina Santos - Strategic Alliance Executive, Cancer Research Horizons
- Lisa Melton - Senior News Editor, Nature Biotechnology
- Katie Anastasi-Frankovics - Head of Innovation and Access, The Wellcome Trust
- Pietro Puglisi - Partner, Claris Ventures
- Florence Bosco - CEO, Quantum BioVenture Studio
- Joachim Keller - Principal, EU Emerging Biopharma, ZS
- Willem van Weperen - CEO, Pluvia Biotech
- Georg Meyer - SVP Head of International, Blueprint Medicines
- Nancy Hunter - VP, Head of Commercial, Zealand Pharma
- Joseph Dagher - SVP, Head of Europe, Cytokinetics
- Helen Tayton-Martin - Chief Business Officer, Adaptimmune
- Melanie Toyne-Sewell - Managing Director, Vigo Consulting
- Ragip M Ziyal - Head of Corporate Development, Tillotts Pharma
- Ingo Lehrke - CBO, Tubulis
- Markus Eustermann - Associate Partner, DTS Patent- und Rechtsanwälte
- Christian Wende - Patentanwalt, European Patent Attorney, Partner, DTS Patent- und Rechtsanwälte
- Sascha Berger - Investment Director, NEOM
- Marc Lohrmann - Investment Partner, KELES
- James Greene - Former CEO, MedLumics
- Kathy Lee-Sepsick - President & CEO, Femasys
- Phil Brown - Director, Regulatory & Compliance, Association of British HeathTech Industries (ABHI)
- Matthias Bellmann - Director Global Focus Team Cardiovascular and Global Strategic Business Development, TÜV SÜD
- Hannes Klöpper - CEO, HelloBetter
- Fiona Costello - SVP Partnerships, Brain+
- Ranjan Singh - Co-founder & CEO, HealthHero
- Jhonatan Bringas Dimitriades - Chief Executive Officer & Co-Founder, Lapsi Health
- Martin Müller - Senior Investment Manager, Carma Fund
- Mark Davies - Chief Health Officer, IBM
- Robert Garber - Managing Partner, 7wire Ventures
- Samana Brannigan - Head of Health Technologies, Innovate UK
- Paula Burke - Director, Life Sciences and Healthcare, HSBC Innovation Banking
- Heather Roxborough - Senior Partner, Head of HealthTech, Oxford Science Enterprises
- David Buller - Managing Partner, KELES
- Rana Lonnen - General Partner, Life Sciences & Tech Venture Fund (Stealth)
- Mathias Vinther - Principal, Forbion
- Mary-Ann Chang - Investor Relations & Communications Advisor, Cohesion Bureau
- Vanela Bushi - Co-founder & GP, H Tree Capital
- Pierre-Louis Joffrin - Associate Partner, Syncona
- Marc Dechamps - CEO, Bioxodes
How to Take Your Company Public: Insights and Strategies for Biotech Success
- When is the right time for a biotech to go public, and what are the key steps to prepare?
- How can companies navigate complex financial and regulatory environments across global markets?
- What do investors look for, and how can biotechs build trust and confidence with them?
- What are the most common pitfalls during the IPO process, and how can they be avoided?
- Linda McGoldrick Ph.D - Board Director, Alvotech
- Edoardo Negroni - Co-Founder & Managing Partner, AurorA-TT
- Herve de Kergrohen - Venture Partner, Alpha Blue Ocean
- Edouard Guillet - MD, IPF Partners
- David Danovitch - Partner, Sullivan & Worcester
- Chuck Bennett - CEO, CORE IR Public & Investor Relations
- Christopher Church - Head of Technology Search and Evaluation, Biopharmaceuticals R&D, AstraZeneca
- Deborah Sterling - Director, Sterne Kessler
- Bernd Muehlenweg - SVP, Global BD, Evotec
- Anja Bitterwolf - to Director, Global Business Development and Licensing, Debiopharm International SA
- Konstantin Petropoulos - CEO, Secarna Pharmaceuticals
- Olga Krylova - Head of S&E, Europe, Global Business Development & Innovation, Otsuka
- Rowan Gardner - CBIO, Precision Life
- Jenny Laird - VP, Search & Evaluation Neuroscience, Eli Lilly and Company
- Sahil Kirpekar - Founder, Lumina Life Sciences
- Rupert Haynes - CEO, Avata Biosciences
- Colleen Acosta - CEO-Founder & CEO, Freya Biosciences
- Paul Holmes - EU Commercialisation Lead, Syneos Health
- Sana Alajmovic - Co-Founder & CEO, Sigrid Therapeutics
- Jenny Barnett - CEO, Monument Therapeutics
- Maria Dahl - COO and Head of Innovent Biologics (Europe), Innovent Biologics
- Sohail Zaidi - CEO, Ananda Scientific
- Paul Beresford - SVP New Product Planning & Business Transformation, iOnctura
- Annie Theriault - Managing Partner, Cross-Border Impact Ventures
- Nicholas Ibery - Venture Capital Investor, NLC Ventures
- Willem Baralt - Chair, Adaptix/Synthace
- Joel Gibbard - CEO & Co-founder, Open Bionics
- Robert Hornby - Investment Director, Mercia Ventures
- Tonya Dowd - EVP, Reimbursement, Health Economics, Market Access, and Corporate Development, PRIA Healthcare
- Isabelle Fourthin - Vice President, Medical Affairs Emerging Markets, Baxter
- Eliane Schutte - CEO, Xeltis
- Assaf Barnea - Managing Partner, Sanara Capital
- Michael Morgan-Curran - CEO, Asclepius MedTech
- Philia Hiotis - Vice President, Strategy & Business Development, EurAsia, Medtronic
- Dominic James - Founder & CEO, Future Centric
- John Drakenberg - Founder & CEO, Alex Therapeutics
- Farnaz Behroozi - Head of Pharma, Huma
- David Benshoof Klein - Founder & CEO, Click Therapeutics
- Nipun Jain - Head of Innovation Hubs & Partnerships for International, AstraZeneca
- Jutta Klauer - Director Strategic Digital Partnerships, MSD
- Toby Basey-Fisher - CEO, Entia
- Katariina Kronholm - Senior Commercial Director, Elekta
- Yahel Halamish - Partner, Nina Capital
- Lu Zheng - VP, Head of Digital Health, Takeda
- Shona D'Arcy - Entrepreneurship Lead, EIT Health
- Alexandra Toader - Director - Global Digital Health, ViiV Healthcare
- Maya Misra - Investment Analyst, Angelini Ventures
Creating a successful biotech company is about more than breakthrough science—it's about building an organization where people and ideas can thrive. In this panel, experienced biotech leaders will discuss how to shape leadership teams and cultural frameworks that drive innovation, resilience, and long-term success. They’ll share hard-earned lessons, practical strategies, and actionable insights for cultivating a dynamic and purpose-driven workplace.
The Role of Leadership in Shaping Culture: How strong, authentic leadership creates a foundation for positive and productive company culture
Meeting Evolving Employee Expectations: What today’s biotech talent values in organizational culture—and how to stay aligned
Culture as a Catalyst: Practical steps to foster innovation, collaboration, and a growth mindset across all levels of the company
- Renee Aguiar-Lucander - Chief Executive Officer, Calliditas Therapeutics
- Christer Ahlberg - CEO, Cinclus Pharma
- Quin Wills - Founder & CSO, Ochre Bio
- Guy Martin - News Editor, The Pharma Letter
- Wanda Rutledge-Gordon - Chief Alliance Officer, Eli Lilly
- Melanie Howard - Partner, Latham & Watkins
- Chris Sheldon - Senior Vice President, Head of Business Development, GSK
- Juergen Eckhardt - EVP, Head of Leaps by Bayer, Head of Pharma BD&L, Bayer
- Matthias Müllenbeck - SVP, Head Global BD & Alliance Management, Merck KGaA
- Linus Rieder - Principal, 415 Capital
- Samantha Schwartz - Director, Healthcare, Eurazeo
- Tatum Getty - Founding General Partner, Thena Capital
- Pieter Wijffels - Venture Partner, NLC Health Ventures
- Hubert Zajicek - CEO, Co-founder & Partner, Health Wildcatters
- Koen Harms - Global Director Strategy & Business Development - ISV & AI partnerships and ecosystems, Philips
- Andreas Wüpper - Managing Director, Fresenius Medical Care Ventures
- Giles Hamilton - Operating Partner, New Growth Advisors
- Stephen Ranjan - Global Head of Digital Health, Roche
- Mike Trenell - CEO & Co-Founder, Daiser
- Damien Marmion - Former Health Insurance Leader, Independent
- Jane Dacre - Emeritus Professor of Medical Education, UCL
- Pritesh Mistry - Fellow (Digital Technologies), The King's Fund
- Barnaby Pickering - Public Relations Associate, RHA Communications
- Pablo Prieto - Managing Director, CG Health Ventures
- Erki Mölder - Managing Partner, Verge Healthtech Fund
- Zach Taft - CEO, IgniteData
- Saemundur Oddsson - Chief Medical Officer & Co-Founder, Sidekick Health
- Tina Tan - Executive Editor, FirstWord HealthTech
- Maite Malet - Investment & Corporate Development, Asabys Partners